Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis
Crossref DOI link: https://doi.org/10.1038/s41433-018-0321-y
Published Online: 2018-12-21
Published Print: 2019-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Douglas, Raymond S.
Text and Data Mining valid from 2018-12-21
Article History
Received: 1 October 2018
Accepted: 1 October 2018
First Online: 21 December 2018
Compliance with ethical standards
:
: The author declares that he has no conflict of interest.